Slide 1: Q3 FY26 Result Presentation
Q3 FY26 Result Presentation 24 April 2026 Mach7 Technologies | ASX: M7T
Slide 2: Our Vision
OUR VISION From pixel to point of care. We win by completing the patient picture with the patient’s pictures, better than anyone else. We will become the core system for imaging data across the enterprise.
Slide 3: Trust will define AI adoption
Trust will define AI adoption. Mach7 positioned to lead in AI-driven healthcare imaging workflows. 3
Slide 4: Q3 FY26 Financial Highlights
Q3 FY26 Financial Highlights Commercial transformation underway A$1.2M A$25.8M A$22.8M OPERATING CF POSITIVE TOTAL CARR1 ARR3 Run Rate Significant +A$0.3M on 31 Dec 2025 +A$0.4M on 31 Dec 2025 improvement on In constant currency2 In constant currency2 Q2 FY26 A$19.2M A$6.0M Lower operating activity
Slide 5: Progressed key elements of strategy
Progressed key elements of strategy Product delivery and execution • Improved customer-aligned product delivery, supported by new technical CTO • Roadmap progress toward enterprise imaging architecture and intelligent cloud orchestration • Early traction in digital pathology, early adopters underway
Slide 6: Partners Activated!
4E Partner Framework PARTNER PROGRAM · Q3 FY26 Enable Engage Execute Expand Partners Activated! 10 Active Partners 4 Strategic Alliances 3 Regional Resellers 1 New International across 4 categories Dell · AWS · Oracle · Ingram signed this year Middle East A scalable, diversified partner ecosystem ac
Slide 7: Flamingo: modular entry point driving future ARR growth
Flamingo: modular entry point driving future ARR growth Strong strategic fit Modular & selling • Supports Pipeline Drive • First customer signed in Q2 enterprise imaging expansion sustainable ARR FY26 strategy • Can be sold to existing • Enables AI, With focus on pipeline Expect contribution to cust
Slide 8: Execution focus areas going into FY27
Execution focus areas going into FY27 Sales momentum Improving with structured pipeline. Delivery execution Execution improving and timelines shortening via new archetype structures and the use of AI. Partner leverage Expanding paths to markets. Leadership and organisational readiness CTO appointmen
Slide 9: Outlook
Outlook FY26 reflects an operational reset year with improvements now visible in cost discipline, pipeline quality and delivery execution. FY26 revenue is expected to be approximately 15% below FY25, reflecting reduced services and delayed conversion of large capital deals, particularly in the Middl
Slide 10: Contact Us
Contact Us Investor Relations, Mach7 Françoise Debelak +61 (0) 412 292 977 ir@mach7t.com Registered Office: Suite 2, Level 11, 385 Bourke St, Melbourne, VIC 3000 This document was authorised for release to the ASX by Teri Thomas, Managing Director and Chief Executive Officer Mach7 Technologies
Slide 11: Disclaimer
Disclaimer “Forward looking” statements Summary of information: This presentation contains general and background information about Mach7 Risks: An investment in M7T securities is subject to investment and other known and unknown risks, Technologies Limited (“M7T”) activities current as at the date